HiberCell
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Pipeline
  • Patients & Caregivers
  • News & Publications
  • Contact
  • Careers
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Pipeline
  • Patients & Caregivers
  • News & Publications
  • Contact
  • Careers

Publication Type: Publication

Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer

Targeting the Integrated Stress Response in Cancer Therapy

PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells

Quantum processor-inspired machine learning in the biomedical sciences

Endoplasmic reticulum stress signals in the tumour and its microenvironment

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

Posts navigation

Older posts
HiberCell
  • About
    • Mission
    • Team
  • Our Science
    • Our Science
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Pipeline
  • News & Publications
  • Contact
  • Careers
Linked In

© 2023 Hibercell Inc |
Privacy Policy |
Terms & Conditions |
Expanded Access